{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "transcribes",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P51679",
      "entity_text" : "CCR4",
      "entity_type" : "gene"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0934" ],
      "CellLine" : [ "cellosaurus:CVCL_D980" ],
      "Organ" : [ "uberon:UBERON:0000479" ],
      "Species" : [ "taxonomy:9606" ],
      "CellType" : [ "cl:CL:0000623" ]
    }
  },
  "verbose_text" : "Mogamulizumab highly enhances antibody dependent cellular cytotoxicity (ADCC) of natural killer cells by binding to CCR4 expressed on tumor cells.5 Although Mogamulizumab can be used for any subtypes of CCR4 positive ATLL, most cases are for aggressive type.6 Efficacy of mogamulizumab for skin lesions is comparatively high.",
  "reading_complete" : "2020-08-02T11:09:59Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T11:09:33Z",
  "trigger" : "expressed",
  "evidence" : [ "CCR4 expressed" ],
  "pmc_id" : "6509667",
  "score" : 0
}